| abstract |
In various aspects, the invention relates to compounds capable of binding to the macrophage inflammatory protein - one alpha (MIP-1alpha) receptors CCR-1, CCR-4, and CCR-5. In various embodiment, the invention provides methods for the use of such compounds in the modulation of processes mediated by such receptors, including in the treatment of diseases, such as diseases mediated by MIP-1alpha, CCR-1, CCR-4 or CCR-5. Pharmaceutical compositions of the compounds of the invention are accordingly provided in alternative aspects of the invention. Compounds of the invention may for example have the following Formula (CTCM111): |